Differential Effect of Three Cyclooxygenase Inhibitors on Human Cerebral Blood Flow Velocity and Carbon Dioxide Reactivity

Hugh S. Markus, MRCP; Patrick Vallance, MRCP; Martin M. Brown, MRCP

Background and Purpose Prostaglandins are believed to play an important role in maintenance of cerebral blood flow and possibly in the vasodilatory response to carbon dioxide. Therefore, the nonsteroidal anti-inflammatory drugs and aspirin, which inhibit cyclooxygenase, might be expected to reduce cerebral blood flow and the response to hypercapnia. This could induce cerebral ischemia in patients with a hemodynamically critical circulation. It would also interfere with the measurement of cerebrovascular reserve using carbon dioxide.

Methods The effect of a single dose of indomethacin and of two other cyclooxygenase inhibitors (aspirin and sulindac) on the cerebral circulation was measured using transcranial Doppler ultrasonography of the middle cerebral artery. Seven normal adults were studied in each drug group. Resting blood flow velocity and the responses to hypercapnia and to hyperventilation were measured.

Results Indomethacin resulted in a fall in basal middle cerebral artery flow velocity from a mean of 48.9 cm/s to 34.0 cm/s (P < .002). It also reduced the vasoconstrictor response to hypercapnia (induced by hyperventilation) from 37.5% to 20.7% (P < .003). There was a nonsignificant reduction in the vasodilatory response to 8% carbon dioxide (mean: predrug, 87.7%; postdrug, 61.0%), with marked intersubject variability. In contrast, basal middle cerebral artery velocity and vasoconstrictor and vasodilatory responses to changes in carbon dioxide were unchanged after aspirin or sulindac administration.

Conclusions The lack of effect of aspirin on basal cerebral blood flow velocity and on vasodilatory reserve is reassuring; aspirin will not reduce cerebral blood flow or the response to a reduced perfusion pressure in patients with critically impaired cerebral hemodynamics. However, indomethacin should be avoided in such patients. (Stroke. 1994;25:1760-1764.)

Key Words: aspirin • ultrasonics • cerebral circulation • indomethacin • prostaglandins
CBF in patients with already reduced cerebrovascular perfusion reserve. These drugs could also interfere with the measurement of cerebrovascular reserve, making predictions based on this test unreliable if the patient is taking aspirin.

To investigate this further we compared the effects of indomethacin and two other cyclooxygenase inhibitors, aspirin and sulindac, on CBF velocity and on the vasodilatory response to hypercapnia. We used the noninvasive technique of transcranial Doppler ultrasonography to measure changes in blood flow velocity.

**Methods**

**Subjects**

In each drug group 7 healthy normal volunteers were studied. All were nonsmokers with no significant past medical history. They had taken no aspirin or nonsteroidal inflammatory drugs in the previous 2 weeks. There was an equal ratio of men to women in each group (6:1). Mean (SD) age in the three groups was not significantly different: indomethacin, 32.6 (6.3) years; aspirin, 35.1 (7.7) years; and sulindac, 34.3 (8.1) years.

**Measurement**

CBF velocity was measured using a transcranial pulsed Doppler ultrasound machine fitted with a 2-MHz probe (TC2000, EME Ltd). The right middle cerebral artery was insonated at a depth of 45 to 52 mm. The probe was held in a fixed position in a specifically designed holder held in place by an elastic strap. All subjects were lying in a semirecumbent position on a couch with the upper half of the body at 30 degrees while measurements were taken. Mean middle cerebral artery blood velocity ($V_m$) was recorded continuously onto an IBM-compatible microcomputer for off-line analysis. Subjects wore a face mask; both inspiratory and expiratory ports were fitted with one-way valves. End-tidal CO$_2$ was monitored continuously (Normacap 200, Datex). End-tidal CO$_2$ was recorded continuously during hypercapnia to measure changes in blood flow velocity.

Blood pressure and pulse during normocapnia were recorded at the start and at 90 and 150 minutes. Pulsatility index was then given, and further measurements were taken at 90 and 150 minutes. Values at times 90 and 150 minutes were expressed as a percentage of the value at time 0 for each subject. A one-way ANOVA was then performed on the summed data for individual subjects followed by Scheffe’s multiple-comparisons test to identify differences between the different groups. In addition, for individual groups mean predrug values were compared with values at 90 minutes using paired $t$ tests. Significance was declared at the $P<.05$ level.

**Results**

Results for the three drugs are summarized in Table 1 (indomethacin), Table 2 (aspirin), and Table 3 (sulindac). $V_m$ during normocapnia fell significantly by a mean of 30.4% after the administration of indomethacin, and this reduction was maintained at 150 minutes. This reduction was seen in all subjects (Figure). In contrast, after both aspirin and sulindac there was no change in $V_m$ during normocapnia (ANOVA, $P<.001$; indomethacin versus aspirin, $P<.005$; indomethacin versus sulindac, $P<.005$). Pulsatility index increased after indomethacin from a mean (SD) of 0.80 (0.18) to 0.94 (0.21) at 90 minutes ($t$ test, $P<.05$). In contrast, pulsatility index did not change after aspirin or sulindac; however, differences between the three groups did not reach significance (ANOVA, $P<.05$). There was no change in pulse, blood pressure, or end-tidal CO$_2$ during normocapnia after administration of any of the three drugs (Tables 1 through 3).

After indomethacin there was a highly variable reduction in the vasodilatory response to hypercapnia; mean fall was 30.4%, but there were great interindividual differences (Figure), with some subjects showing an almost complete abolition of vasodilatory response, and others showing little change. There was no difference in the levels of end-tidal CO$_2$ reached during inspiration of 8% CO$_2$ between the studies before and after indomethacin. There was no change in the vasodilatory response to hypercapnia after either aspirin or sulindac. Differences between the three groups were not significant (ANOVA, $P=4$).

After indomethacin administration all subjects showed a reduced vasoconstrictor response to hyperventilation by a mean of 44.7%. The levels of end-tidal CO$_2$ reached during hyperventilation were unchanged after indomethacin. The results were similar when the fall in $V_m$ during hyperventilation was divided by the fall in end-tidal CO$_2$ during hyperventilation: before indomethacin, 26.1% (SD, 11.5%); 90 minutes after indomethacin, 13.0% (SD, 9.19); change, 50.4%. In contrast, there was no change in the response to hyperventilation.
TABLE 1. Values of Cerebral Blood Flow Velocity, Vasodilatory and Vasoconstrictor Responses, Pulsatility Index, and Arterial Blood Pressure Before and 90 and 150 Minutes After 100 mg Indomethacin

<table>
<thead>
<tr>
<th>Time</th>
<th>V&lt;sub&gt;max&lt;/sub&gt; cm/s</th>
<th>Vasodilatory Response, %</th>
<th>Vasoconstrictor Response, %</th>
<th>PI</th>
<th>ETCO&lt;sub&gt;2&lt;/sub&gt; Normocapnia, kPa</th>
<th>Systolic BP, mm Hg</th>
<th>Diastolic BP, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-1</td>
<td>48.9</td>
<td>87.7</td>
<td>37.5</td>
<td>0.80</td>
<td>4.56</td>
<td>113.0</td>
<td>81.4</td>
</tr>
<tr>
<td></td>
<td>(11.0)</td>
<td>(42.2)</td>
<td>(14.0)</td>
<td>(0.18)</td>
<td>(0.91)</td>
<td>(10.8)</td>
<td>(7.2)</td>
</tr>
<tr>
<td>Pre-2</td>
<td>48.0</td>
<td>85.8</td>
<td>37.4</td>
<td>0.79</td>
<td>4.27</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>90 Min</td>
<td>34.0</td>
<td>61.0</td>
<td>20.7</td>
<td>0.94</td>
<td>4.34</td>
<td>109.9</td>
<td>84.6</td>
</tr>
<tr>
<td></td>
<td>(12.8)</td>
<td>(35.8)</td>
<td>(17.0)</td>
<td>(0.21)</td>
<td>(0.54)</td>
<td>(9.3)</td>
<td>(6.5)</td>
</tr>
<tr>
<td>150 Min</td>
<td>34.8</td>
<td>81.9</td>
<td>20.0</td>
<td>0.94</td>
<td>4.36</td>
<td>111.6</td>
<td>63.7</td>
</tr>
<tr>
<td></td>
<td>(11.8)</td>
<td>(39.7)</td>
<td>(14.9)</td>
<td>(0.21)</td>
<td>(0.80)</td>
<td>(9.2)</td>
<td>(5.3)</td>
</tr>
</tbody>
</table>

P values
pre-1 vs 90 min .002 NS .003 .028 NS NS NS

V<sub>max</sub> indicates middle cerebral artery blood velocity; PI, pulsatility index; ETCO<sub>2</sub>, end-tidal CO<sub>2</sub>; BP, blood pressure; Pre, pretreatment; and NS, not significant.

Standard deviations are shown in parentheses. Probability values from f test comparisons between the first baseline measurement and the measurement at 90 minutes are shown.

Discussion

Our results demonstrate that indomethacin results in a rapid fall in CBF velocity. The 30% reduction in basal CBF velocity after indomethacin is similar to the 20% to 40% reduction in CBF reported previously in animals and in humans. This coupled with an increase in pulsatility index indicates that it exerts a vasoconstrictor action. We also found that indomethacin significantly reduces the vasoconstrictor response to hypocapnia induced by hyperventilation. In contrast to the uniformity of the reduction in resting V<sub>max</sub> and in the vasoconstrictor response, which was seen in all subjects (Figure), indomethacin resulted in a variable reduction in the vasodilatory response to CO<sub>2</sub>. In some individuals this response was markedly decreased, whereas in others there was little change. This marked interindividual variability in the inhibition of the vasodilatory response may be the reason why previous studies in humans have revealed conflicting results. In these studies the mean data from a group of subjects were analyzed, and this method of presentation may obscure the interindividual variability. In one study no control group received hypercapnia; a significant increase in CBF was seen with a very modest increase in CO<sub>2</sub> concentration from 5.0 to 5.5 kPa, but this may represent a nonspecific response to the stress of the mask and the CO<sub>2</sub>. Furthermore, without a control group it is unclear whether the response to hypercapnia was reduced compared with normal subjects, as the trend in our study suggested, or was unaltered as found by Pickles et al. However, other studies revealing conflicting results induced greater changes in end-tidal CO<sub>2</sub> concentrations, similar to those attained in our study, and used ade-

TABLE 2. Values of Cerebral Blood Flow Velocity, Vasodilatory and Vasoconstrictor Responses, Pulsatility Index, and Arterial Blood Pressure Before and 90 and 150 Minutes After 1200 mg Aspirin

<table>
<thead>
<tr>
<th>Time</th>
<th>V&lt;sub&gt;max&lt;/sub&gt; cm/s</th>
<th>Vasodilatory Response, %</th>
<th>Vasoconstrictor Response, %</th>
<th>PI</th>
<th>ETCO&lt;sub&gt;2&lt;/sub&gt; Normocapnia, kPa</th>
<th>Systolic BP, mm Hg</th>
<th>Diastolic BP, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-1</td>
<td>45.1</td>
<td>103.5</td>
<td>41.1</td>
<td>0.63</td>
<td>4.46</td>
<td>109.4</td>
<td>76.1</td>
</tr>
<tr>
<td></td>
<td>(10.4)</td>
<td>(54.7)</td>
<td>(12.1)</td>
<td>(0.08)</td>
<td>(0.67)</td>
<td>(4.7)</td>
<td>(5.7)</td>
</tr>
<tr>
<td>Pre-2</td>
<td>45.9</td>
<td>101.8</td>
<td>40.4</td>
<td>0.61</td>
<td>4.45</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>90 Min</td>
<td>42.9</td>
<td>100.3</td>
<td>40.1</td>
<td>0.66</td>
<td>4.45</td>
<td>112.6</td>
<td>77.7</td>
</tr>
<tr>
<td></td>
<td>(7.5)</td>
<td>(45.1)</td>
<td>(9.8)</td>
<td>(0.10)</td>
<td>(0.58)</td>
<td>(3.6)</td>
<td>(3.6)</td>
</tr>
<tr>
<td>150 Min</td>
<td>43.7</td>
<td>107.7</td>
<td>38.0</td>
<td>0.63</td>
<td>4.59</td>
<td>110.0</td>
<td>77.1</td>
</tr>
<tr>
<td></td>
<td>(9.1)</td>
<td>(50.7)</td>
<td>(15.8)</td>
<td>(0.09)</td>
<td>(0.34)</td>
<td>(2.5)</td>
<td>(6.2)</td>
</tr>
</tbody>
</table>

Abbreviations as in Table 1.

Standard deviations are shown in parentheses. There were no significant changes in any parameter after aspirin.
TABLE 3. Values of Cerebral Blood Flow Velocity, Vasodilatory and Vasoconstrictor Responses, Pulsatility Index, and Arterial Blood Pressure Before and 90 and 150 Minutes After 300 mg Sulindac

<table>
<thead>
<tr>
<th>Time</th>
<th>$V_{max}$, cm/s</th>
<th>Vasodilatory Response, %</th>
<th>Vasoconstrictor Response, %</th>
<th>PI</th>
<th>ETCO$_2$, Normocapnia, kPa</th>
<th>Systolic BP, mm Hg</th>
<th>Diastolic BP, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-1</td>
<td>49.3</td>
<td>81.4</td>
<td>44.1</td>
<td>0.69</td>
<td>5.31</td>
<td>109.4</td>
<td>76.1</td>
</tr>
<tr>
<td></td>
<td>(7.5)</td>
<td>(51.1)</td>
<td>(8.0)</td>
<td>(0.07)</td>
<td>(0.39)</td>
<td>(4.7)</td>
<td>(5.7)</td>
</tr>
<tr>
<td>Pre-2</td>
<td>49.6</td>
<td>77.8</td>
<td>45.6</td>
<td>0.65</td>
<td>4.73</td>
<td></td>
<td>...</td>
</tr>
<tr>
<td></td>
<td>(4.4)</td>
<td>(46.4)</td>
<td>(8.7)</td>
<td>(0.08)</td>
<td>(0.32)</td>
<td></td>
<td>...</td>
</tr>
<tr>
<td>90 Min</td>
<td>50.0</td>
<td>77.9</td>
<td>40.9</td>
<td>0.69</td>
<td>4.80</td>
<td>112.6</td>
<td>77.7</td>
</tr>
<tr>
<td></td>
<td>(11.5)</td>
<td>(53.0)</td>
<td>(12.3)</td>
<td>(0.11)</td>
<td>(0.33)</td>
<td>(3.6)</td>
<td>(3.6)</td>
</tr>
<tr>
<td>150 Min</td>
<td>47.0</td>
<td>84.5</td>
<td>40.6</td>
<td>0.66</td>
<td>4.87</td>
<td>110.0</td>
<td>77.1</td>
</tr>
<tr>
<td></td>
<td>(6.9)</td>
<td>(58.1)</td>
<td>(13.8)</td>
<td>(0.11)</td>
<td>(0.41)</td>
<td>(2.5)</td>
<td>(6.2)</td>
</tr>
</tbody>
</table>

Abbreviations as in Table 1. Standard deviations are shown in parentheses. There were no significant changes in any parameter after sulindac.

patients with already compromised cerebral hemodynamics, in some of whom a further fall in CBF might result in the precipitation of cerebral ischemia. Furthermore, in some individuals the use of indomethacin will interfere with the measurement of cerebrovascular reserve as assessed by administering CO$_2$. This will be a greater problem if the measurement of cerebrovascular reserve used includes the sum of response to both hyperventilation as well as hypercapnia because the response to hyperventilation was reduced in all subjects.

In contrast, the two other cyclooxygenase inhibitors aspirin and sulindac had no effect on resting CBF velocity or on the responses to hyperventilation or hypercapnia. Therefore, the use of aspirin will not interfere with this measurement of cerebrovascular reserve and is unlikely to prove dangerous in patients with impaired cerebrovascular hemodynamics.

The subjects in our study were healthy volunteers. We felt it was unethical to proceed to a study in which patients with carotid stenosis and impaired cerebrovascular reserve were given indomethacin. However, our results are likely to apply to such patients. This is supported by our findings in one patient who presented with left amaurosis fugax and a 60% ipsilateral carotid stenosis confirmed on angiography, with a 20% contralateral stenosis. At presentation he was taking 25 mg indomethacin three times a day. At this time $V_{max}$ was 27 cm/s in the right and 36 cm/s in the left. Indomethacin was withdrawn, and $V_{max}$ rose to 37 cm/s right and 40 cm/s left. After a single dose of 50 mg indomethacin, $V_{max}$ fell (right, 30 cm/s; left, 34 cm/s).

All three drugs we used are potent inhibitors of prostaglandin synthesis. Sulindac is the nonsteroidal agent most similar structurally to indomethacin. The lack of effect of aspirin and sulindac on CBF velocity suggests that indomethacin may reduce CBF by a method other than inhibition of prostaglandin synthesis, as proposed by Eriksson et al. Indomethacin is known to have inhibitory actions on a number of enzyme and cellular systems in addition to its inhibition of prostaglandin synthesis. In a study in anesthetized pigs it had a rapid-acting (within 60 seconds) systemic vasoconstrictor effect that preceded any change in prostanoid release and was thought to be independent of cyclooxygenase inhibition. Few animal studies have looked at the effect of prostaglandin inhibitors other
than aspirin, and the results have been conflicting.\textsuperscript{5,20} Only one human study, using the nitrous oxide washout technique, has looked at the effect of prostaglandin inhibitors other than indomethacin in normal adults; naproxen and aspirin had no effect on CBF or reactivity to CO\textsubscript{2}, whereas indomethacin did reduce both parameters in this study.\textsuperscript{18} Our results support these findings. It is possible that effects on V\textsubscript{max} were not seen with aspirin and sulindac because the doses given did not adequately inhibit prostaglandin synthesis. However, both sulindac and aspirin, at lower doses than those given in our study, result in marked inhibition of platelet aggregation in humans in vivo.\textsuperscript{21} It is more difficult to assess the inhibition of vascular prostacyclin in vivo; however, 300 mg of aspirin (a dose much smaller than we used) results in over 80\% inhibition of prostacyclin production by human vein.\textsuperscript{22} It has been suggested that aspirin has no effect because it does not adequately cross the blood-brain barrier,\textsuperscript{18} and this remains a possible explanation. However, studies in pigs have demonstrated that aspirin and other nonsteroidal agents inhibited the cerebrovascular production of prostaglandins to as great a degree as indomethacin, yet only indomethacin reduced CBF.\textsuperscript{20}

In summary, our results have direct clinical implications in that indomethacin should be avoided in patients with critical cerebral hemodynamics or in CO\textsubscript{2} cerebrovascular reserve testing. In contrast, aspirin and sulindac in the doses we used appear safe and will not interfere with cerebrovascular reserve testing. Our results raise the possibility that the predominant effect of indomethacin on the cerebral circulation is through mechanisms other than prostaglandin inhibition. This should be borne in mind when studying the cerebral circulation, and other cyclooxygenase should be used in addition to indomethacin in pharmacological studies of prostaglandin inhibition.

Acknowledgments
Hugh Markus is supported by the British Heart Foundation. We thank Dr Martin Bland for statistical help.

References


Differential effect of three cyclooxygenase inhibitors on human cerebral blood flow velocity and carbon dioxide reactivity.
H S Markus, P Vallance and M M Brown

Stroke. 1994;25:1760-1764
doi: 10.1161/01.STR.25.9.1760
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1994 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/25/9/1760